Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients

Tumor Biology

Volumn 37, Issue 7, 2016, Pages 9323-9331

  Zhang, Fan ^a   Chen, Zhaoli ^a   Wang, Pan ^a   Hu, Xueda ^a   Gao, Yibo ^a   He, Jie ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Esophageal squamous cell cancer; Mean platelet volume; Platelet count; Prognosis; Scoring system

Indexed keywords

CA 19-9 ANTIGEN; D DIMER; HEMOGLOBIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CLOTTING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EARLY CANCER; ERYTHROCYTE PARAMETERS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NEUTROPHIL LYMPHOCYTE RATIO; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RED BLOOD CELL DISTRIBUTION WIDTH; RETROSPECTIVE STUDY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84954451487     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4774-3     Document Type: Article

References (41)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J Cancer. 2012;136(5):E359–86.
2. Zhang SW, Zhang M, Li GL, Wei WQ, Meng FS, Liu ZC, et al. An analysis of incidence and mortality of oesophageal cancer in China, 2003–2007. China Cancer. 2012;21:241–7.
3. Mao YS, He J, Cheng GY. Current status of surgical management of esophageal cancer in China and the future strategy. Zhonghua Zhong Liu Za Zhi. 2010;32:401–4.
4. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.
5. Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008;68:26–33.
6. Harada K, Ida S, Baba Y, Ishimoto T, Kosumi K, Tokunaga R, et al. Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma. Dis Esophagus. 2015. doi:10.1111/dote.12381.
7. Zheng YZ, Wen J, Cao X, Yang H, Luo KJ, Liu QW, et al. Decreased mRNA expression of transcription factor forkhead box F2 is an indicator of poor prognosis in patients with resected esophageal squamous cell carcinoma. Mol Clin Oncol. 2015;3(3):713–9.
8. Tong M, Chan KW, Bao JY, Wong KY, Chen JN, Kwan PS, et al. Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma. Cancer Res. 2012;72:6024–35.
9. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3(1):27–34.
10. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol. 2002;3(7):425–30.
11. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123–34.
12. Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001;22(17):1561–71.
13. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–8.
14. Gorelick C, Andikyan V, Mack M, Lee YC, Abulafia O. Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population. Int J Gynecol Cancer. 2009;19:1384–9.
15. Ishizuka M, Oyama Y, Abe A, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients undergoing surgery for gastric cancer. J Surg Oncol. 2014;110:935–41.
16. Josa V, Krzystanek M, Eklund AC, Salamon F, Zarand A, Szallasi Z, et al. Relationship of postoperative thrombocytosis and survival of patients with colorectal cancer. Int J Surg. 2015;18:1–6.
17. Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, et al. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res. 2005;25:709–13.
18. Kurt M, Onal IK, Sayilir AY, Beyazıt Y, Ozta SE, Kekilli M, et al. The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease. Hepato-Gastroenterology. 2012;59:1580–2.
19. Karaman K, Bostanci EB, Aksoy E, Kurt M, Celep B, Ulas M, et al. The predictive value of mean platelet volume in differential diagnosis of nonfunctional pancreatic neuroendocrine tumors from pancreatic adenocarcinomas. Eur J Intern Med. 2011;22:95–8.
20. Kılınçalp S, Ekiz F, Başar O, Ayte MR, Coban S, Yılmaz B, et al. Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelets. 2014;25(8):592–4.
21. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.
22. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315(16):983–9.
23. Kapoor JR. Platelet activation and atherothrombosis. N Engl J Med. 2008;358(15):1638.
24. Connolly GC, Phipps RP, Francis CW. Platelets and cancer-associated thrombosis. Semin Oncol. 2014;41(3):302–10.
25. Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res. 2014;133 Suppl 2:S149–57.
26. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004;30(1):95–108.
27. Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology. 2000;58(2):169–74.
28. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004;5(11):655–63.
29. Li X, Chen ZH, Xing YF, Wang TT, Wu DH, Wen JY, et al. Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol. 2015;36(4):2263–9.
30. Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, et al. Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma. J Surg Res. 2015;198(1):73–9.
31. Zhang H, Zhang L, Zhu K, Shi B, Yin Y, Zhu J, et al. Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort study. PLoS One. 2015;10(5), e0126496. doi:10.1371/journal.pone.0126496.
32. Aksoy S, Kilickap S, Hayran M, Harputluoglu H, Koca E, Dede DS, et al. Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors. Int J Lab Hematol. 2008;30(3):214–9.
33. Osada J, Rusak M, Kamocki Z, Dabrowska MI, Kedra B. Platelet activation in patients with advanced gastric cancer. Neoplasma. 2010;57(2):145–50.
34. Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer. 2014;83(1):97–101.
35. Cho SY, Yang JJ, You E, Kim BH, Shim J, Lee HJ, et al. Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets. 2013;24(5):375–7.
36. Oge T, Yalcin OT, Ozalp SS, Isikci T. Platelet volume as a parameter for platelet activation in patients with endometrial cancer. J Obstet Gynaecol. 2013;33(3):301–4.
37. Kumagai S, Tokuno J, Ueda Y, Marumo S, Shoji T, Nishimura T, et al. Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer. Mol Clin Oncol. 2015;3(1):197–201.
38. Li JY, Li Y, Jiang Z, Wang RT, Wang XS. Elevated mean platelet volume is associated with presence of colon cancer. Asian Pac J Cancer Prev. 2014;15(23):10501–4.
39. Kissova J, Bulikova A, Ovesna P, Bourkova L, Penka M. Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms. Int J Hematol. 2014;100(5):429–36.
40. Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H. Elucidating the correlation between treatment with tyrosine kinase inhibitors and mean platelet volume in patients with metastatic renal cell cancer. Oncol Lett. 2014;8(5):2249–52.
41. Wei XL, Wang FH, Zhang DS, Qiu MZ, Ren C, Jin Y, et al. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer. 2015;15:350.